-+ 0.00%
-+ 0.00%
-+ 0.00%

Incyte To Present New Data From Dermatology Portfolio At EADV 2025 Congress

Benzinga·09/10/2025 11:33:05
Listen to the news

- 24-week data from the Phase 3 STOP-HS clinical trial program of povorcitinib in patients with hidradenitis suppurativa (HS) selected as a late-breaking oral presentation

Today Incyte (NASDAQ:INCY) announced that it will present new data from its dermatology portfolio at the European Association of Dermatology and Venerology (EADV) 2025 Congress, held from September 17 – 20, in Paris. Highlights include late-breaking, oral and poster presentations featuring data for povorcitinib (INCB054707), an oral small-molecule JAK1 inhibitor, and ruxolitinib cream (Opzelura®), a topical JAK1/2 inhibitor.